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S
ystemic lupus erythematosus (SLE) is a clinical 
condition that fascinates physicians, scientists and 
laymen, possibly due to some characteristics, such 
as unpredictability, multifaceted phenotype, potential 
morbidity and its etiopathogenesis mystery. These features 
permeate several aspects of SLE, making it one of the most 
difficult diseases to manage clinically. Among several others, 
two challenges have a special place in scientific and clinical 
SLE forums: definition of type and degree of renal activity, 
and definition of activity status and quiescence of this disease. 
Despite researchers’ efforts, these are two problems in clinical 
practice for which there is no easy and generic solution, but 
relative and specific solutions for each case. This edition of 
Brazilian Journal of Rheumatology brings two relevant studies 
on these topics. 
Melo et al.1 made an interesting approach on clinical and 
histological correlation in diagnosis and therapeutic analysis 
of lupus nephritis. In this study, the authors carried out a re-
trospective analysis of 100 consecutive SLE cases followed 
by lupus nephritis at Department of Rheumatology of Santa 
Casa de Misericórdia de São Paulo. The goal was to compare 
therapeutic response at 12 and 24 months related to several 
variables at the beginning of treatment and according to the 
nephritis class alternately established based on histological 
analysis or clinical judgment. Although it was not a prospective 
and controlled study, the authors have benefited from the fact 
that the therapeutic regimen recommended in the service is 
standardized and regularly used, so there was an acceptable 
homogeneity in this item. To forms considered milder (class 
II), corticosteroid was used at 1mg/kg/day doses; and to more 
severe forms (classes III, IV and V), classical regime was 
used, based on induction with intravenous cyclophosphamide 
and methylprednisolone and maintenance with azathioprine 
or mycophenolate mofetil. 
During observation period, there was a favorable response 
in most patients, with 72.7% of patients reaching total remis-
sion at 12 months and 85.7% at 24 months. Partial remission 
was observed in 27.3% of patients at 12 months and in 14.3% of 
patients at 24 months. Although follow-up had been relatively 
short, these cases are encouraging, especially when considering 
conditions not always ideal for support, due to poor medical 
assistance in public health service. As expected, a significant 
portion of patients presented relapse, most during maintenance 
phase, but there was favorable response after adjusting corti-
costeroid and immunosuppressant doses. 
Considering the influence of several variables on thera-
peutic response, authors found some interesting findings. As 
expected, men presented a lower rate of total remission (45.5%) 
compared with women. This confirms the notion already 
established of a worse prognosis of lupus nephritis in men. 
Clinical and laboratory variables assigned in the beginning of 
treatment could not distinguish patients who presented total 
remission from those with partial remission at 12 months. 
However, it is noteworthy mentioning that serum creatinine 
levels and leucocyturia levels presented trends to higher values 
in patients who presented only partial remission. 
The most relevant contribution of this study was the inge-
nious comparative analysis between the clinical and laboratory 
judgment and the histopathological examination to define 
glomerulonephritis class related to therapeutic result. It is 
interesting to say that parameters referring to disease activity, 
urinary changes and serum Complement consumption did not 
differ among patients defined as class IV by histological crite-
rion or clinical and laboratory judgment. This finding seems 
to suggest a reasonable equivalence between both criteria. 
However, therapeutic response was clearly more favorable 
in patients defined as class IV by the clinical and laboratory 
trial than in group defined by histological criterion. These 
findings may be interpreted in various ways. A reasonable 
interpretation is that in the group selected according to the 
clinical and laboratory judgment there could be patients who-
se histological classification did not correspond to class IV, 
although clinic and laboratory manifestations had suggested. 
As possible representatives of histological classes II and III, 
these patients may have diverted this group to a higher index 
of total remission. This rationale is consistent with the concept 
that histological criterion is more accurate in predicting clinical 
evolution. This interpretation may suggest that renal biopsy 
can be assigned more liberally. However, it may also reinforce 
the idea that, for most of the cases, the clinical and laboratory 
judgment may be sufficient for initial decision made by an 
expert physician, and that therapeutic response may represent 
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an additional parameter to conduct these cases. Thus, the work 
of Melo et al. reaffirms this issue complexity and confronts 
the possibility of two different and complementary ways of 
approaching lupus nephritis. 
Another intriguing aspect in SLE research is the search of 
authentic parameters to monitor inflammatory activity. Several 
parameters have been proposed such as serum levels of some 
autoantibodies, Complement components determination, acute 
phase reactants, evaluation of urinary sediment and hemati-
metric index, and others. 
Among autoantibodies, the following antibody levels are 
highlighted: native anti-DNA, anti-nucleosome, anti-C1q and 
ribosomal anti-P. Several studies have shown that these autoan-
tibodies tend to elevate their levels during periods of increased 
disease activity and tend to decline or even disappear during 
periods of remission. Although antibodies against extractable 
nuclear antigen (SS-A/Ro, SS-B/La, Sm and U1-RNP) also 
present fluctuation during the illness, there is no evidence of 
correlation with inflammatory activity2 also there is no evidence 
that antinuclear antibody (ANA or antibodies against cell cons-
tituents) has association with disease activity. This association 
with serum levels of antibodies against native DNA, nucleo-
some, C1q and ribosomal P protein seems to suggest that such 
autoantibodies have a real physiopathologic role in some SLE 
patients. However, such association is far from being absolute, 
since many patients do not comply. Additionally, a great part 
of patients does not show these autoantibodies in any moment 
of the disease. Thus, certain autoantibody levels in SLE have a 
true role, but restrict, in monitoring SLE activity. 
Because one of SLE physiopathologic pathways is based 
on deposition of immune complexes and Complement system 
activation, it is natural that monitoring this system component 
is useful in SLE activity follow-up. During many decades, 
total hemolytic activity of Complement has been measured, 
as well as serum levels of some components in this system, 
as support to monitor disease activity in SLE. Although there 
is association between Complement consumption and disease 
activity, especially in lupus nephritis, there are several cases of 
disagreement, mainly in non renal manifestation. Part of this 
disagreement possibly comes from the fact that component 
levels of Complement suffer influence from external variables, 
such as pool replacement rate variability, increment of synthe-
sis as an effect of acute phase response and wide variation of 
normality values. More recently, some authors have proposed 
to measure degradation product of Complement, such as C4a, 
C3a and Bb, that would not suffer such influences.3 The per-
formance of these parameters in monitoring disease activity 
remains under trial. 
Theoretically, acute phase proteins would be rational para-
meters to monitor the activity of inflammatory diseases, such 
as SLE. Curiously, however, this is not seen systematically in 
practice. Normally, patients are seen with no evident signal of 
disease activity and presenting consistently high levels of C-
reactive protein (CRP) and elevated erythrocyte sedimentation 
rate. Reciprocally, it is not uncommon to see patients in full 
activity and with normal or minimally changed values. This 
paradox probably hides some uncommon aspect and possibly 
of great interest for understanding SLE physiopathology. 
As a consequence of laboratory parameter limits available 
to monitor SLE activity, several researchers continue searching 
more efficient alternatives. In this edition of Brazilian Journal 
of Rheumatology, Carvalho et al. documented a new and inte-
resting parameter with potential association with SLE disease 
activity.4 Lipoprotein lipase (LPL) antibodies were recently 
described in SLE and in other autoimmune diseases.5-7 These 
autoantibodies present correlation with triglyceride serum le-
vels. Carvalho et al. had previously demonstrated that anti-LPL 
antibodies have correlation with some parameters of disease 
activity, such as hypocomplementemia, ultrasensitive CRP and 
SLEDAI.6 In this edition, these authors suggest an interesting 
dual behavior of these autoantibodies based on case report 
of 5 patients. In patients with consistently quiescent disease, 
anti-LPL antibodies were kept stable and in high levels. On the 
other hand, anti-LPL levels oscillate in patients with unstable 
disease, with periods of activity alternating with periods of 
quiescence. This is an intrigant finding and it will certainly 
stimulate additional studies to establish possible differences 
in subpopulations of anti-LPL antibodies in such contexts, as 
well as define their use in monitoring SLE disease activity. 
The search for excellence is a human characteristic in all 
areas in which this restless being works; sometimes this search 
aims an utopian solution, of absolute simplicity and solvability. 
The Holy Grail, Philosopher’s Stone and Moto Continuum 
are archetypal representations of this feature of our species. 
However, real progress along our history has been achieved 
by concrete and infinitesimal efforts; brick by brick, mortar, 
dream and sweat. So has been the conquest of systemic lupus 
erythematosus. There is no magic, no absolute parameter. The 
Holy Grail is a mixture of cumulative knowledge from studies, 
such as those mentioned before, mature clinical experience, 
technical excellence, commitment to help the patient and ability 
to have a humble judgment in front of each case. 
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